Navigation Links
Epothilone in Medical News
Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma
...upportive trial in patients with less advanced disease. Kosan's Hsp90 and epothilone Clinical Programs on Track for 2008 Kosan's TIME registration program is ...ancer who have not previously been treated with trastuzumab. Kosan's lead epothilone clinical candidate, KOS-1584, has demonstrated promising antitumor activity...Study Findings Could Help In Developing A Better Drug Delivery System
...hat is in phase I studies. Endocyte has licensed its vitamin-targeting technology to Bristol-Myers Squibb to target Bristol-Myers Squibb's proprietary epothilone cancer chemotherapeutic agents. Source-Eurekalert VI ...Epothilone in Medical Technology
Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
HAYWARD, Calif., April 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) today announced that the Phase 2 trial of epothilone KOS-1584 in patients with non-small cell lung cancer has been initiated. The Phase 2 trial is an open-label, multi-center, monotherapy study ...HAYWARD, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) presented updated data today from a Phase 1 clinical trial showing that KOS-1584/R1645, an epothilone under co-development with Roche, demonstrated antitumor activity and tolerability in patients...
Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
HAYWARD, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated today presented preclinical data on KOS-1803, a next-generation epothilone, showing a high level of antitumor activity and a favorable pharmacokinetic and safety profile in a broad range of in vitro tests and ...HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented data from a Phase 1 clinical trial showing that KOS-1584/R1645, an epothilone under co-development with Roche, demonstrated promising antitumor activity and tolerability in patients with solid tumors....
...atic breast cancer in combination with Herceptin(R) (trastuzumab). KOS-1584 epothilone product candidate is in a Phase 2 clinical trial in patients with non-small...s; Kosan' dependence on it license with Bristol-Myers Squibb to develop its epothilone products in order for Kosan to receive milestones or royalties, Kosan's dep...
Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
...Company's clinical and preclinical pipeline, including its Hsp90 inhibitor, epothilone and nuclear export inhibitor programs, at the 2007 Annual Meeting of the Am...S-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercial...Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
...lar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. For additional information on Kosan Biosciences, pleas...Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
...lar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. For additional information on Kosan Biosciences, pleas......lar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. For additional information on Kosan Biosciences, pleas...
...lar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. For additional information on Kosan Biosciences, pleas...
Epothilone in Biological Technology
Kosan to Reacquire Epothilone Program From Roche
Kosan to Commence Phase 2 Clinical Program for KOS-1584 HAYWARD, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) today announced that Roche and Kosan are concluding their epothilone development and commercialization collaboration. The collabora...PRINCETON, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY ) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of IXEMPRA(TM) (ixabepilone) as monotherapy for the treatment of patients with metastatic or locally advanced brea...
Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
...arkets and her work with a broad range of compound classes and tumor types will be of significant value to Kosan as we advance our Hsp90 inhibitor and epothilone programs through later stages of development," said Helen S. Kim, Kosan's President and Chief Executive Officer. "Recruiting an experienced and accomp...Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
...rams, tanespimycin in multiple myeloma and in metastatic breast cancer, and epothilone KOS-1584 in non-small lung cancer. The restructuring will primarily affect ...pany's reputation as a leader in polyketide technology as well as Hsp90 and epothilone drug discovery. We believe that this restructuring will strengthen our abil...Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
...loma and in metastatic breast cancer, and its lead epothilone candidate, KOS-1584, in non-small cell lung cancer...herapy beginning in late 2008 and early 2009. -- epothilone KOS-1584 is a key asset in Kosan's pipeline. Kosan...hanisms. With the recent FDA approval of the first epothilone (BMS' ixabepilone), the epothilone class has gaine...Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
...ter is primarily due to increased clinical costs in the Hsp90 inhibitor and epothilone programs, including costs associated with the initiation of the clinical tr...espimycin metastatic breast cancer clinical program, and the development of epothilone KOS-1584, which is entering Phase 2 in non-small cell lung cancer. We belie......on and sustainability of multiple partnering arrangements and license agreements with third parties, including with respect to its Hsp90 inhibitor and epothilone programs; Kosan's need for additional financing; Kosan's ability to obtain valid and enforceable patents covering its product candidates; Kosan's depe...
Kosan Announces Third Quarter 2007 Financial Results
...gram in multiple myeloma and investment in Kosan's epothilone program, including KOS-1584 process development wh...nnounced that Roche and Kosan are concluding their epothilone development and commercialization collaboration. T...which Kosan will reacquire worldwide rights to its epothilone program and have full control of clinical developm...Other TagsOther Contents
(Date:5/21/2013)... 21, 2013 Phoseon Technology will present ... the 20th Annual IMI European Ink Jet Conference ... leader, Phoseon continues to invest in product development to ... of UV LED curing in printing applications. Phoseon ... the market offering both air cooled and water cooled ...
(Date:5/21/2013)... Modern couples have countless strains ... Counseling’s Sexuality and Relationship Workshops, couples are learning ... healthier habits for their relationship. There are both ... and individuals at Texas Counseling. Their goal is ... skills to develop long term solutions. , ...
(Date:5/21/2013)... of Defense Serum Repository (DoDSR), University of Cincinnati (UC) ... bowel disease (IBD), which could help with earlier diagnosis ... symptoms. , This finding, the first of its kind ... presented via podium presentation by staff from Walter Reed ... being held May 18-21 in Orlando, Fla. , ...
(Date:5/21/2013)... The Las Vegas personal injury law firm Benson, ... Gates, a senior at Coronado High School, is the winner ... . As the winner of the essay contest, Crawford received ... Dec. 1, 2012 and ran through April 30th, 2013. Participating ... minimum essay on “The Role of the civil tort system.” ...
(Date:5/21/2013)... A new study appearing in the current issue ... harvested from fat (adipose) are more potent than those ... body’s immune system. , The finding could have ... tissue-derived stem cells (AT-SCs) are far more plentiful in ... can be collected from waste material from liposuction procedures. ...
Breaking Medicine News(10 mins):Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Benson, Bertoldo, Baker & Carter is Pleased to Announce the Winner of its First Annual College Scholarship Essay Contest 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 3[0] Phoseon Technology Presents the Leading UV LED Curing Solutions at IMI European Ink Jet Conference[0] Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships[0] Biomarkers discovered for inflammatory bowel disease[0] Benson, Bertoldo, Baker & Carter is Pleased to Announce the Winner of its First Annual College Scholarship Essay Contest[0] Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease
(Date:5/18/2013)... AGA Research Foundation is honored to announce the first ... Cancer, which will support Andrew D. Rhim, MD, from ... Pennsylvania, Philadelphia, as he furthers his research on the ... progression. , "The AGA Research Foundation is humbled to ... and AGA Legacy Society members," said Nicholas F. LaRusso, ...
(Date:5/18/2013)... (May 18, 2013) An increasing number of ... interventions to resolve, according to research presented at ... study targeting obesity, researchers at the Cleveland Clinic ... unique pattern of exhaled breath compared to their ... organic compound levels that can be correlated to ...
(Date:5/17/2013)... State University of New Jersey, and City University of ... Visikol TM that effectively clears organisms to be ... of chloral hydrate, which is one of the few ... regulated by the Drug Enforcement Administration (DEA) due to ... clearing agents, are vital for viewing organisms under a ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |